When pharmacodynamics trump costs: An antimicrobial stewardship program's approach to selecting optimal antimicrobial agents

Clinical Therapeutics

Volumn 35, Issue 6, 2013, Pages 766-771

  Goff, Debra A ^a   Nicolau, David P ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Antimicrobial stewardship; Carbapenems; Cefepime; Cost; Pharmacodynamics; Prolonged infusions

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CILASTATIN PLUS IMIPENEM; DORIPENEM; IMIPENEM; MEROPENEM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; CRITICALLY ILL PATIENT; DRUG COST; DRUG POTENCY; HOSPITALIZATION; HUMAN; LUNG LAVAGE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; ADULT; COMPARATIVE STUDY; DRUG EFFECTS; ECONOMICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; PSEUDOMONAS INFECTIONS;

ADULT; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CEPHALOSPORINS; DRUG COSTS; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 84879450481     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.05.004     Document Type: Article

References (16)

1. Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
2. Vincent J.L., Rello J., Marshall J., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
3. Mouton J.W. Breakpoints: current practice and future perspectives. Int J Antimicrob Agents 2002, 19:323-331.
4. Kuti J.L., Nicolau D.P. Making the most of surveillance studies: summary of the OPTAMA program. Diagn Microbiol Infect Dis 2005, 53:281-287.
5. Crandon J.L., Bulik C.C., Kuti J.L., Nicolau D.P. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010, 54:1111-1116.
6. Lodise T.P., Lomaestro B., Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44:357-363.
7. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Information Supplement. Document M100-S20-U 2010, Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute, Wayne, Pa.
8. Janssen Pharmaceuticals Inc. Doribax, doripenem for injection. Accessed March 1, 2013. http://www.doribax.com.
9. Koomanachai P., Bulik C.C., Kuti J.L., Nicolau D.P. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010, 32:766-779.
10. DeRyke C.A., Kuti J.L., Nicolau D.P. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy 2007, 27:333-342.
11. Roberts J.A., Kwa A., Montakantikul P., et al. Pharmacodynamic profiling of intravenous antibiotics against prevalent gram-negative organisms across the globe: the PASSPORT program-Asia-pacific region. Int J Antimicrob Agents 2010, 37:225-229.
12. Kollef M.H. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000, 31(Suppl 4):S131-S138.
13. Bhat S.V., Peleg A.Y., Lodise T.P., et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother 2007, 51:4390-4395.
14. Bauer K., West J., Goff D.A. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2013 Apr 9, [E-pub ahead of print].
15. Eagye K.J., Kuti J.L., Sutherland B.S., et al. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at forty US hospitals. Clin Ther 2009, 31:2678-2688.
16. US Food and Drug Administration. FDA Statement on recently terminated clinical trial with Doribax (doripenem). Accessed May 6, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm285883.htm.